English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Osmotically controlled oral drug delivery systems utilize osmotic pressure as energy source for the controlled delivery of drugs, independent of pH and hydrodynamic conditions of gastro intestinal tract (GIT). The present study was aimed to develop osmotic controlled extended release formulations of Losartan potassium an angiotensin II receptor antagonist with anti-hypertensive activity. Losartan potassium matrix tablets were prepared by direct compression process using HPMC K 15M as polymeric material and mannitol as osmogen at varied concentrations. The matrix tablets were further coated with different compositions of ethylcellulose7cps and PEG-4000 by pan coating method. Physical parameters such as weight uniformity, drug content, hardness and friability were evaluated for uncoated tablets and were found to be within I.P limits. The coating thickness and percentage of coating applied for various tablets were also evaluated. The optimized coated tablets were further subjected to micro drilling on the upper face to get 0.5μm orifice diameter. All the tablets were further subjected to dissolution studies by using USP apparatus II with distilled water as medium. These studies indicated that all the tablets were found to release the drug up to 12 hours, while coated tablets with orifice found to release the drug at zero order rate, which was in good agreement with peppas n values >0.9.

Formulation and Evaluation of Losartan Potassium Osmotic Controlled Matrix Tablets